FFAR3 and fatty liver disease: Butyrate, acetate, and propionate participate in the improvement of hepatic steatosis, either by activating the GPR41 and GPR43 receptors located within the target tissues (adipose tissue, intestine, liver) or by directly acting locally without binding to their receptors [2].